Amit Sachdev - Feb 1, 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Chief Patient Officer
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Feb 1, 2023
Transactions value $
$0
Form type
4
Date filed
2/3/2023, 03:56 PM
Previous filing
Mar 11, 2022
Next filing
Feb 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Gift $0 -1.67K -13.14% $0.00 11.1K May 17, 2022 Held in Trust
transaction VRTX Common Stock Award $0 +10.3K +19.35% $0.00 63.7K Feb 1, 2023 Direct F1
transaction VRTX Common Stock Award $0 +8.21K +12.89% $0.00 71.9K Feb 1, 2023 Direct F2
transaction VRTX Common Stock Award $0 +7.87K +10.94% $0.00 79.8K Feb 1, 2023 Direct F3
holding VRTX Common Stock 882 Feb 1, 2023 401(k)
holding VRTX Common Stock 8.86K Feb 1, 2023 Held in Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest on 02/13/2023.
F2 Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest in installments beginning on 02/24/2023.
F3 Restricted stock unit award that vests in installments beginning on 02/10/2024.